血液透析动静脉移植物与肥胖对通畅率的影响:一项回顾性研究
本回顾性研究纳入2006年1月至2010年12月本中心放置的143例动静脉移植物(AVG),比较肥胖与非肥胖患者的通畅率及干预结局。结果显示肥胖并非AVG丧失通畅的危险因素,两组总体通畅率、技术失败率、干预需求及感染率均无显著差异;作者认为肥胖患者自体动静脉内瘘(AVF)选项耗尽或不可用时,可考虑放置AVG。
要点
- 肥胖与非肥胖组AVG总体通畅率在1、3、5年无显著差异(P=0.85)。
- 肥胖并非AVG丧失通畅的危险因素。
- 肥胖患者AVF选项耗尽或不可用时,作者认为可考虑放置AVG。
核心结论
- 较高的BMI和肥胖不是AVG丧失的危险因素。
- 肥胖患者的总体通畅率不劣于非肥胖AVG。
- 作者认为,肥胖患者自体动静脉内瘘(AVF)选项耗尽或不可用时,可考虑放置AVG。
研究设计与样本
- 回顾性研究,纳入2006年1月至2010年12月本中心放置的143例AVG。
- 数据从电子记录中回顾性收集,分为肥胖组与非肥胖组。
- 主要终点为AVG血栓形成,次要终点为死亡、肾移植或失访。
- 记录移植物通畅率和首次干预结局,使用IBM SPSS 20分析,P值<0.05认为显著。
主要发现
- 随访时间为669 ± 708天(均值±标准差,最小值0天,最大值3,042天)。
- 0.49%(70例)的移植物放置于肥胖患者,BMI范围为17至51 Kg/m2(29.8 ± 8)。
- 肥胖组与非肥胖组技术失败率无差异(12.9% vs. 11%,P=0.56,Fisher精确检验)。
- 肥胖组与非肥胖组总体通畅率在1、3、5年无显著差异(肥胖组54%、25%、17% vs. 非肥胖组56%、30%、18%,P=0.85,Log-rank Kaplan-Meier)。
- 肥胖组与非肥胖组成功率(88.2% vs. 83.3%,P=0.73,Fisher精确检验)、需要超过1次干预的比例(61.8% vs. 61.1%,P=1.0,Fisher精确检验)及感染率(10% vs. 9.6%,P=1.0,Fisher精确检验)均相似。
临床怎么用
- 作者认为,肥胖患者AVF选项耗尽或不可用时,可考虑放置AVG。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is growing in the hemodialysis (HD) population. Few scholars report variable effects of increased body mass index (BMI) on native fistula. Reports on obesity effects on arteriovenous graft (AVG) patency are lacking. We report our experience. METHODS: AVGs placed in our center between January 2006 and December 2010 were included. Data were collected retrospectively from electronic records. The primary end point was AVG thrombosis. The secondary end points were death, kidney transplant, or lost to follow-up. Graft patency and first intervention outcome were recorded. Study groups were divided into obese and nonobese groups. IBM SPSS 20 was used for analysis. A P value < 0.05 was considered significant. RESULTS: 143 AVGs were included. The follow-up was 669 ± 708 [0, 3,042 days (mean ± SD, min, max)], and 0.49% (70) of grafts were placed in obese patients. The BMI ranged between 17 and 51 Kg/m2 (29.8 ± 8). There was no difference in the technical failure rate between obese and nonobese groups (12.9% vs. 11%, P=0.56, Fisher's exact test). Obesity was not a risk factor of loss of patency. No significant difference was observed in the overall patency between obese (54%, 25%, and 17%) and nonobese groups (56%, 30%, and 18%) at 1, 3, and 5 years. (P=0.85, Log-rank Kaplan -Meier). Similarly, the success rate (88.2% vs. 83.3%, P=0.73, Fisher's exact test) and requirement of more than 1 intervention (61.8% vs. 61.1%, P=1.0, Fisher's exact test) were similar. Finally, the infection rate was similar in both groups (10% vs. 9.6%, P=1.0, Fisher's exact test) CONCLUSIONS: Higher BMI and obesity were not risk factors for AVG loss. Overall patency in obese patients is not inferior to that in nonobese AVGs. In obese patients, AVG insertion should be considered if the native arteriovenous fistula (AVF) options are exhausted or not available.
引用
- Hassan A, Boyes SA. Hemodialysis Arteriovenous Graft and The Effect of Obesity on Patency. A Retrospective Study. Ann Vasc Surg. 2024. PMID: 39701209. doi:10.1016/j.avsg.2024.11.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。